Attention Deficit Hyperactivity Disorder (ADHD) Market Report

Attention Deficit Hyperactivity Disorder (ADHD) Market Analysis By Medication (Stimulants And Non-stimulants), By Psychotherapy (Behavioral, Cognitive, Family And Marital), By Distribution Channel (Specialty Clinics, Hospital & Retail), 2014 To 2025

Format: PDF  |  Report ID: GVR3667

Attention Deficit Hyperactivity Disorder (ADHD) is a brain disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. It may begin in early childhood and can continue into adulthood. Without treatment, ADHD can cause problems at home, at school, at work, and with relationships. In the past, ADHD was termed as Attention Deficit Disorder (ADD). The exact cause is not known, but ADHD tends to run in families. Boys are about three times more likely than girls to be diagnosed with it.

There are three main types of ADHD symptoms:

Trouble paying attention- People with ADHD are easily distracted. They have a hard time focusing on any one task; Trouble sitting still for even a short time: This is called hyperactivity. Children with ADHD may squirm, fidget, or run around the wrong times. Teens and adults often feel restless and fidgety. They are not able to enjoy reading or performing other quiet activities; And Acting before thinking: People with ADHD may talk too loud, laugh too loud, or become angrier than the situation calls for. ADHD symptoms can appear as early as between the ages of 3 and 6 and thus ADHD is termed as neuro developmental disorder and can continue through adolescence and adulthood. ADHD symptoms can change over time as a person ages.

The global ADHD therapeutics market is segmented on the basis of medication, age group, therapy, distribution channel, and region.

For many people, ADHD medications reduce hyperactivity and impulsivity and improve their ability to focus, work, and learn. On the basis of medication the market size covers Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate): Stimulant is the most common type of medication used for treating ADHD. It increases the brain chemicals dopamine and norepinephrine, which play important roles in thinking and attention; Non-stimulants (Atomoxetine, Bupropion, Guanfacine, and Clonidine): These medications take longer to start working than stimulants, but can also improve focus, attention, and impulsivity in a person with ADHD. Although not approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of ADHD, some antidepressants are sometimes used alone or in combination with a stimulant to treat ADHD.

Based on age group, the ADHD market size covers pediatric, adolescent, and adults.

Based on the therapy market size constitutes psychotherapy and its sub types. Adding psychotherapy to treat ADHD can help patients and their families to better cope with everyday problems. Behavioral therapy is a type of psychotherapy that aims to help a person change his or her behavior. It involves practical assistance or working through emotionally difficult events, and also teaches to monitor his/her behavior, controlling anger or thinking before acting. Cognitive behavioral therapy teaches a person mindfulness techniques, or meditation. Family and marital therapy helps family members and spouses find better ways to handle disruptive behaviors, improve interactions with the patient.

Based on the distribution channel, the market size comprises specialty clinics, hospital pharmacies, retail pharmacies, and e-commerce.

Based on geography the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America accounted for the largest share of global ADHD therapeutics market in 2015. This was because of availability of good healthcare infrastructure, presence of clinical ongoing trials, the early approval of therapeutics in the U.S., existence of insurance policies for brain monitoring technologies, and government support for technological advancement. Asia Pacific region is expected to be the fastest growing segment during the forecast period, due to growing healthcare industry, government initiatives, presence of huge population, and rising number of mental disorders.

The major key players are as follows:

Shire plc, Neos Therapeutics, Inc., Eli Lilly and Company, Pfizer Inc., Alcobra Ltd., Supernus Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., Novartis AG, Johnson & Johnson, and Curemark, LLC.

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA